Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data
暂无分享,去创建一个
Scott Boyer | Niklas Blomberg | Gert Strandlund | Claire L. Gavaghan | Catrin Hasselgren Arnby | C. H. Arnby | S. Boyer | N. Blomberg | G. Strandlund | C. Gavaghan
[1] P. Carrupt,et al. Molecular fields in quantitative structure–permeation relationships: the VolSurf approach , 2000 .
[2] Antranig Basman,et al. HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. , 2004, Progress in biophysics and molecular biology.
[3] J. Valentin,et al. Nonclinical proarrhythmia models: predicting Torsades de Pointes. , 2005, Journal of pharmacological and toxicological methods.
[4] T. Nishikawa,et al. A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[5] Pierre Bruneau,et al. Search for Predictive Generic Model of Aqueous Solubility Using Bayesian Neural Nets , 2001, J. Chem. Inf. Comput. Sci..
[6] John Sharkey,et al. Acquired QT interval prolongation and HERG: implications for drug discovery and development. , 2004, European journal of pharmacology.
[7] A. Bass,et al. Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies. , 2005, Journal of pharmacological and toxicological methods.
[8] M Pastor,et al. VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[9] Brian B. Goldman,et al. A model for identifying HERG K+ channel blockers. , 2004, Bioorganic & medicinal chemistry.
[10] J. Li,et al. A two-state homology model of the hERG K+ channel: application to ligand binding. , 2005, Bioorganic & medicinal chemistry letters.
[11] Gabriele Cruciani,et al. Predictive models for hERG potassium channel blockers. , 2005, Bioorganic & medicinal chemistry letters.
[12] Derek J Trezise,et al. IonWorks™ HT: A New High-Throughput Electrophysiology Measurement Platform , 2003, Journal of biomolecular screening.
[13] Rober t C. Glen. A fast empirical method for the calculation of molecular polarizability , 1994, J. Comput. Aided Mol. Des..
[14] Erik Johansson,et al. Megavariate analysis of hierarchical QSAR data , 2002, J. Comput. Aided Mol. Des..
[15] A. Brown,et al. Drugs, hERG and sudden death. , 2004, Cell calcium.
[16] F. Österberg,et al. Exploring blocker binding to a homology model of the open hERG K+ channel using docking and molecular dynamics methods , 2005, FEBS letters.
[17] W. Crumb,et al. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. , 2002, The Journal of pharmacology and experimental therapeutics.
[18] S. Wold. Cross-Validatory Estimation of the Number of Components in Factor and Principal Components Models , 1978 .
[19] A. Cavalli,et al. QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development , 2005, Medicinal research reviews.
[20] J. Gasteiger,et al. ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .
[21] Alex M Aronov,et al. Predictive in silico modeling for hERG channel blockers. , 2005, Drug discovery today.
[22] Matthew Clark,et al. Development and Evaluation of an in Silico Model for hERG Binding , 2006, J. Chem. Inf. Model..
[23] Glenn J. Myatt,et al. LeadScope: Software for Exploring Large Sets of Screening Data , 2000, J. Chem. Inf. Comput. Sci..
[24] Douglas M. Hawkins,et al. Assessing Model Fit by Cross-Validation , 2003, J. Chem. Inf. Comput. Sci..
[25] G. Keserü. Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. , 2003, Bioorganic & medicinal chemistry letters.
[26] Michael C Sanguinetti,et al. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. , 2005, Trends in pharmacological sciences.
[27] B. Small,et al. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. , 2006, Journal of pharmacological and toxicological methods.
[28] Roy J. Vaz,et al. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. , 2003, Bioorganic & medicinal chemistry letters.
[29] T G Hammond,et al. Use of in vitro methods to predict QT prolongation. , 2005, Toxicology and applied pharmacology.
[30] J. Hancox,et al. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652 , 2003, British journal of pharmacology.
[31] Michael Markert,et al. Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization. , 2004, Journal of pharmacological and toxicological methods.
[32] A. Camm,et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.
[33] Gisbert Schneider,et al. A Virtual Screening Method for Prediction of the hERG Potassium Channel Liability of Compound Libraries , 2002, Chembiochem : a European journal of chemical biology.
[34] R. Rasmusson,et al. Functionally-distinct proton-binding in HERG suggests the presence of two binding sites , 2007, Cell Biochemistry and Biophysics.
[35] R Purdy,et al. A mechanism-mediated model for carcinogenicity: model content and prediction of the outcome of rodent carcinogenicity bioassays currently being conducted on 25 organic chemicals. , 1996, Environmental health perspectives.
[36] Bernd Beck,et al. Onion design and its application to a pharmaceutical QSAR problem , 2004 .
[37] S C Basak,et al. Predicting acute toxicity (LC50) of benzene derivatives using theoretical molecular descriptors: a hierarchical QSAR approach. , 1997, SAR and QSAR in environmental research.
[38] A. Cavalli,et al. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. , 2002, Journal of medicinal chemistry.